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Abstract 
Objective: Vulvovaginal atrophy (VVA), caused by decreased levels of estrogen, is a common 
problem in aging women. Main symptoms of VVA are vaginal dryness and dyspareunia. First-line 
treatment consists of the application of local estrogen therapy (ET) or vaginal moisturizer. In 
some cases however, symptoms and signs persist despite those interventions. This case study 
describes a 77-year-old woman with severe VVA symptoms despite use of local ET and the 
addition of pelvic floor muscle (PFM) training to her treatment. 
Methods: A patient with stress urinary incontinence and VVA was referred to a randomized 
clinical trial on PFM training. On pretreatment evaluation while on local ET, she showed VVA 
symptoms on the ICIQ Vaginal Symptoms questionnaire and the ICIQ-Female Sexual Matters 
associated with lower urinary tract Symptoms questionnaire, and also showed VVA signs during 
the physical and dynamometric evaluation of the PFM. She was treated with a 12-week PFM 
training program. 
Results: The patient reported a reduction in vaginal dryness and dyspareunia symptoms, as well 
as a better quality of sexual life after 12 weeks of PFM training. On posttreatment physical 
evaluation, the PFMs’ tone and elasticity were improved, although some other VVA signs 
remained unchanged. 
Conclusions: Pelvic floor muscle training may improve some VVA symptoms and signs in women 
taking local ET. Further study is needed to investigate and confirm the present case findings and 
to explore mechanisms of action of this intervention for VVA. 
  
Vulvovaginal atrophy (VVA) is a common condition that affects 39% to 63% of postmenopausal 
women.1 It results from decreased estrogen in the vulvovaginal tissues,2 leading to blood flow 
reduction,3 and the degeneration of collagen and elastin fibers,2-5 as well as pH and epithelium 
cell changes.2,6 These modifications cause a reduction of lubrication and sebaceous gland 
secretions, a loss of vulvovaginal tissue elasticity, and an environment more receptive to 
colonization by pathogenic bacteria.3,7 In patients with symptomatic VVA, an increase in pelvic 
floor muscle (PFM) tone can also be observed because of a protective guarding response 
triggered by pain and discomfort.8,9 VVA leads to vaginal dryness, pruritus, dyspareunia, urinary 
incontinence (UI), and increased frequency of vaginitis and urinary tract infection.1,2,7 All have 
negative impacts on general and sexual quality of life.1,10 
Most common VVA treatments include local hormonal therapy (HT), systemic HT, application of 
vaginal moisturizer, and use of vaginal lubricants.3,11 According to the Society of Obstetricians 
and Gynaecologists of Canada and The North American Menopause Society, some of these 
treatments, however, may be not suitable for some patients, due to a variety of reasons (ie, risk 
of developing endometrial and breast cancer, allergies) and may be related to adverse effects 
(ie, vaginal irritation, vaginal bleeding, breast pain, nausea).3,7 In addition, according to a 
Cochrane systematic review, one study comparing estradiol ring treatment (a form of local HT) 
to placebo showed that 31% of women still felt vaginal dryness with this treatment.12 
Dyspareunia also seemed to persist in some women treated with local estrogen therapy (ET) 
according to this Cochrane systematic review: in two studies comparing estrogen tablets to 
placebo, 20% to 31% of women still had dyspareunia.12 Therefore, there is a real need to 
investigate safe, effective, and low-cost complementary treatments. 
PFM training refers to an exercise program, which specifically targets the PFM. It is usually 
taught and supervised by a health professional such as a physiotherapist.13 PFM training has 
proven to be an effective treatment for UI,14 genital prolapse,15-17 and dyspareunia.18,19 It is 
generally recommended as first-line treatment as it has been associated with low-cost and 
minimal adverse effects.14 PFM training could be beneficial for alleviating VVA symptoms and 
signs. Indeed, in a randomized control trial (RCT) investigating PFM training for UI, some women 
with VVA reported improvement of their VVA symptoms after the intervention. The case report 
below describes one of the participants in this RCT. 
CASE REPORT 
A 77-year-old multiparous woman was referred by her urogynecologist to the GROUP trial 
(Clinical trial.gov number NCT02039830). The objective of this noninferiority RCT was to 
compare the cost-effectiveness of group-based PFM training to individualized PFM training in 
the treatment of UI for women aged 60 and over. The PFM training program was the same in 
both groups; the only difference being its mode of delivery, that is either as group session or 
individual sessions. 
At pretreatment assessment, the participant complained of stress UI for 7 years and reported six 
urinary leakages per week mainly associated with coughing, walking, and effort as reported in a 
1-week bladder diary. Other than UI, her actual general health was excellent. Her previous 
surgical history included abdominal hysterectomy without ovariectomy, cystocele repair, 
rectocele repair, and abdominal colposacropexy. She had been on oral ET for 10 years up to age 
of 70. She was taking local ET (Premarin 0.625 mg/g × 0.5 g) once a week for 2 years. 
This woman was sexually active, having intercourse with her husband (approximately three 
times per month). She had severe VVA symptoms, as measured by questionnaires related to 
urogynecological health (namely the ICIQ Vaginal Symptoms questionnaire [ICIQ-VS] and the 
ICIQ-Female Sexual Matters associated with lower urinary tract Symptoms questionnaire [ICIQ-
FLUTSsex]). She reported her symptoms had begun 3 years ago. 
The ICIQ-VS questionnaire assesses the severity of vaginal symptoms and associated sexual 
matters on quality of life using scales from “Never” to “All of the time” and from “Not at all” to 
“A lot.”20 On this questionnaire (see Table 1), the woman reported feeling vaginal dryness and 
vaginal tightness “All of the time.” Both symptoms bothered her a lot (8/10 and 10/10 on visual 
analogue scale [VAS], respectively). Furthermore, she expressed being worried “A lot” about 
VVA's impact on her sex life and feeling that her relationship with her partner was affected by 
vaginal symptoms “A little.” Those declarations bothered her 10/10 and 5/10 on VAS, 
respectively. Finally, she reported that her sex life had been spoiled considerably by her vaginal 
symptoms (8/10 on a VAS) and that those symptoms interfered with her everyday life (4/10 on 
VAS).  
TABLE 1 Questionnaires concerning vaginal atrophy
  
The ICIQ-FLUTS sex questionnaire values the sexual matters associated with lower urinary tract 
symptoms using scale from “Not at all” to “A lot.”21 In this questionnaire (see Table 1), the 
woman complained of “A little” pain or discomfort because of a dry vagina and of “Somewhat” 
dyspareunia. Those symptoms bothered her at 3/10 and at 8/10 on VAS, respectively. 
After completing the questionnaires, a physical therapy examination and a pelvic floor 
assessment were performed by an experienced physical therapist. More specifically, it included 
observations of the vulvovaginal area with the Vaginal Atrophy Index (VAI),22 PFM tone 
assessment with the Reissing scale,8 and PFM tone and antero-posterior aperture assessment 
with a pelvic floor dynamometer 23 (see Table 2).  
 TABLE 2 Physical examination 
  
The VAI assesses the following six elements: vulvar skin elasticity, pubic hair, labia, vaginal 
mucosa, vaginal depth, and transverse introitus breadth, each on a scale from 1 to 3 or 1 to 2.22 
Scores from 6/15 to 11/15 are related to more severe VVA; scores from 12/15 to 14/15 are 
related to slighter VVA; and a score of 15/15 represents no VVA according to Leiblum et al.22 In 
this index, we observed poor vulvar skin elasticity, sparse pubic hair, atrophic and dry labia, as 
well as smooth vaginal mucosa (absence of rugae) for this participant. The participant had 
normal vaginal depth and transverse introitus breadth (two fingerbreadths). Her total score on 
the VAI was 10/15 indicative of more severe VVA according to Leiblum scale. 
Through vaginal digital palpation, the Reissing scale gives a subjective measure of PFM tone 
using a seven-point scale from -3 (hypotonic muscle) to +3 (hypertonic muscle) with normal 
value at 0.8 The participant showed some increased in PFM tone with a score of +1 on the right 
side, the left side, and the bottom. 
The dynamometric speculum is an intravaginal dynamometer that can measure passive forces 
(tone) at different introital openings. At pretreatment assessment, the woman's passive force 
(tone) with the speculum branches closed to minimal aperture (10 mm) was 1.42 N. When the 
dynamometer was open to maximal aperture, she had a somewhat reduced maximal antero-
posterior introital aperture of 20.47 mm as compared with the mean opening for women of her 
age without VVA of 24.82 mm (unpublished data from our laboratory database). 
After the pretreatment assessment, the participant was randomized in the group-based PFM 
training for an intensive physical therapy treatment, including weekly 1 hour PFM training 
supervised by another experienced physical therapist as described previously.24 Each session 
consisted of a 15-minute educational segment and a 45-minute exercise component. The 
educational segment covered PFM functions, different PFMs’ problems, and women's health 
advices on UI (ie, liquid intake, constipation, and urgency control). The PFM exercise component 
included strength, endurance, and coordination exercises, as well as functional rehabilitation. 
More specifically, the participant did in each PFM training session maximal PFM contractions, 
fast PFM contractions, PFM contraction before and during a cough (the “knack” exercise), and 
an endurance exercise including a moderate PFM contraction, a maximal PFM contraction, and 
another PFM moderate contraction. Furthermore, PFMs were trained during functional 
activities.24 The treatment protocol was divided into three phases allowing for a gradual 
training progression, that is the gradual addition of increasingly difficult exercises in terms of 
duration, repetition, and position. Each phase lasted 4 weeks. The women had to perform the 
four PFM exercises included in the PFM training sessions at home, 5 days a week, for the 
duration of the treatment. To support training progression at home, the home-based exercise 
program was parallel to the three phases in the treatment protocol and also included gradual 
addition of increasingly difficult exercises every 4 weeks. 
During the treatment phase (3 mo), the participant did her PFM exercises five times a week as 
recorded in her exercise diary for exercise compliance. She applied her local ET once a week 
during the treatment as she had done in the past 2 years. 
After treatment, a posttreatment assessment was conducted. The woman showed a reduction 
of UI symptoms. On the 1-week bladder diary, there was a reduction in urinary leakage of 
66.7%, that is she had only two urinary leakages per week instead of six. The “minimal clinically 
important difference” for the bladder diary is considered to be a 50.0% reduction of urinary 
leakage which was attained.25 
Improvement of some of her VVA symptoms and signs was also observed. On the ICIQ-VS 
questionnaire (see Table 1), she reported to “Never” feeling vaginal dryness anymore (reduction 
of 4/5 points on the questionnaire scale) and only “Occasionally” vaginal tightness (reduction of 
3/5 points). Both symptoms bothered her less after the treatment (0/10 and 2/10 on VAS 
respectively, both reductions of 8/10 points). She reported she was not worried anymore about 
VVA's impacts on her sex life (reduction of 3/4 points) and VVA did not affect her relationship 
with her partner anymore (reduction of 1/4 points). Therefore, she was not worried about those 
statements (both 0/10 on VAS, reduction of 10/10 points and 5/10 points, respectively). Finally, 
VVA did not affect her sex life as much as it did before, nor her overall quality of life, as she 
rated 1/10 on VAS for both items (a reduction of 7/10 points and 3/10 points, respectively). 
On the ICIQ-FLUTS sex questionnaire, the woman reported that she was not feeling any pain or 
discomfort because of a dry vagina anymore (reduction of 1/4 points), and that it did not bother 
her anymore (reduction of 3/10 points). She noted having “A little” dyspareunia (a reduction of 
1/4 points) that bothered her less (2/10 on VAS; a reduction of 6/10 points). 
On the posttreatment physical assessment, some improvements were observed, as well. 
Initially, on the VAI, only skin elasticity improved from “poor” to “fair.” Sparse pubic hair, 
atrophic and dry labia, and smooth vaginal mucosa were still observed, as well as normal vaginal 
depth and normal transverse introitus breadth (two fingerbreadths). Therefore, the total score 
of the VAI improved by 1/15 points, from 10/15 to 11/15. On the Reissing scale, the participant 
showed a normal tone with a score of 0 (a change of 1 point). These results corroborated with 
the posttreatment dynamometer assessment findings. Indeed, her passive force (tone) with the 
dynamometer close (10 mm opening) was decreased from 1.42 to 0.986 N (a reduction of 31%). 
In addition, her maximal antero-posterior introital aperture increased from 20.47 to 25.15 mm 
(an increase of 23%). 
DISCUSSION 
In regards to this 77-year-old woman, VVA caused significant symptoms and signs despite her 
following local ET. Symptoms of this pathology had negative impacts on her sex life and her 
everyday life. The participant also initially presented VVA signs of poor vulvar skin elasticity, 
sparse pubic hair, atrophic and dry labia, smooth vaginal mucosa, increased PFM passive force 
(tone), and decreased antero-posterior introital opening. After 3 months of PFM training, the 
woman appeared to have an important improvement in her VVA symptoms and signs. 
The results of this case report are interesting and novel. To our knowledge, no other study 
investigated the effect of PFM training on VVA symptoms and signs. On the contrary, some 
studies looked at PFM training on global sexual function in incontinent women and had positive 
results.26-28 Liebergall et al 26 reported this global sexual function improvement after 12 
weeks of PFM training in RCT (60 UI women), whereas Zahariou et al 27 and Beji et al 28 
reported it in cohort studies after 12 months of PFM training (58 UI women) and 6 weeks of 
PFM training (42 UI women), respectively. Dyspareunia was also assessed and improved in those 
two cohort studies,27,28 but Liebergall's results were not statistically significant.26 The 
population of those studies was, however, different from the women with VVA population, as 
they were mainly younger premenopausal women. In Liebergall's study, mean age was 46.6 
years old (SD = 8.9), and the authors did not give information about their menopausal status. In 
Zahariou's study, mean age was 43 ± 6.2 years old and 24.14% of participants were 
postmenopausal women. Finally, in Beji's study, mean age was 43.5 ± 6.4 years old and 26.2% of 
participants were postmenopausal women with ET. 
The effects of PFM training were also evaluated in gynaecological cancer survivors with similar 
vaginal symptoms to women with VVA by Yang et al.29 Indeed, those women frequently feel 
less vaginal lubrication, less vaginal elasticity, and experience dyspareunia after being treated 
for their cancer.30 In Yang et al's RCT, this population aged from 35 to 67 years old significantly 
improved their sexual function and quality of life after 4 weeks of PFM training.29 
The positive effects of PFM training on VVA that we have observed may be explained by 
different hypotheses. To begin with, PFM training could improve vulvovaginal blood flow. It is 
well recognized that skeletal muscle exercises contribute to increasing the number of capillaries 
in trained muscles.31 Because PFM arteries also supply the vulvovaginal tissues, PFM training 
could improve vulvovaginal blood flow and lead to a better vaginal lubrication as well as tissue 
quality. A similar hypothesis was introduced by Leiblum et al in an observational study with 
postmenopausal women in which sexually active women had significantly less overall VVA than 
sexually inactive women (P = 0.004).22 Increased blood flow to the pelvic organs by regular 
sexual activity would provide protection from VVA according to the author.22 It can be 
hypothesized that PFM training has an effect similar to intercourse on vulvovaginal blood flow. 
In a second hypothesis, PFM training could improve elasticity of vulvovaginal tissues by 
repetitively mobilizing the different tissues’ layers with repeated PFM contractions over time. 
Decreased estrogen at menopause makes collagen fibers fuse and undergo hyalinization, which 
leads to loss of mucosal elasticity as well as narrowing and shortening of the vagina.2 As shown 
in Madill et al with anatomical MRI, after 12 weeks of PFM training, a maximal PFM voluntary 
contraction lifts the urethrovesical junction approximately 7 mm (from 13.45 ± 5.53 mm to 
20.42 ± 7.30 mm).32 These tissues’ mobilization could result in improved skin elasticity, an 
increased antero-posterior introital opening as well as a decreased feeling of vaginal tightness. 
This hypothesis can also explain why women with regular sexual activity have less VVA as vaginal 
penetration and stimulation also provokes vaginal tissues’ mobilization. 
Furthermore, the reduction of urinary leakage could lead to pH normalization. Zahariou et al 
elaborated this hypothesis in a cohort study including 12 months of PFM training.27 According 
to them, urinary leakages could modify vaginal pH, affecting the normal flora and leading to 
vaginal dryness as well as loss of lubrication.27 Reduction of urinary leakages would normalize 
vaginal pH, leading to VVA symptoms’ improvement. 
Finally, PFM training could normalize PFM tone. The PFM exercises included in the 3-month 
program consist of repeated contractions and relaxations of PFM,14 which could have helped 
the women to be more aware of those muscles. Decreased PFM tone on posttreatment 
dynamometric assessment has also been shown by Madill et al 32 in a cohort study with 
incontinent women 60 years of age and over, after 12 weeks of PFM training (P = 0.047). 
Furthermore, Glazer et al in a cohort study of 33 women with provoked vestibulodynia after a 
16-week biofeedback-assisted PFM training also noted a PFM resting tone decrease of 68%, 
using electromyographic evaluation.33 So, PFM training seems to help women learn how to 
relax those muscles, which can be very useful during intercourse to reduce vulvovaginal tissues’ 
frictions and dyspareunia. 
The accidental discovery of potential VVA symptoms and signs improvement after PFM training 
in our noninferiority RCT is of high interest because of the simplicity, low cost, and absence of 
side effects of the intervention.14 It is also possible that these findings, however, may be 
related to a placebo effect or chance effect. A study with more robust methodology including a 
higher number of participants and targeting both VVA objective and subjective outcomes is 
needed to confirm the present case findings/results. 
 
CONCLUSIONS 
The positive effects of PFM training in a postmenopausal woman with VVA have potential 
implications for treatments of VVA symptoms and signs. Further study is needed to investigate 
and confirm the present case findings and to explore mechanisms of action of this intervention 
on VVA. 
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